144 related articles for article (PubMed ID: 29288782)
1. Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting.
Rendle KA; Schiffman M; Cheung LC; Kinney WK; Fetterman B; Poitras NE; Lorey T; Castle PE
Prev Med; 2018 Apr; 109():44-50. PubMed ID: 29288782
[TBL] [Abstract][Full Text] [Related]
2. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
Silver MI; Schiffman M; Fetterman B; Poitras NE; Gage JC; Wentzensen N; Lorey T; Kinney WK; Castle PE
Cancer; 2016 Dec; 122(23):3682-3686. PubMed ID: 27657992
[TBL] [Abstract][Full Text] [Related]
3. Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting.
Landy R; Schiffman M; Sasieni PD; Cheung LC; Katki HA; Rydzak G; Wentzensen N; Poitras NE; Lorey T; Kinney WK; Castle PE
Int J Cancer; 2020 Feb; 146(3):617-626. PubMed ID: 30861114
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
5. A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
Hammer A; Demarco M; Campos N; Befano B; Gravitt PE; Cheung L; Lorey TS; Poitras N; Kinney W; Wentzensen N; Castle PE; Schiffman M
Int J Cancer; 2020 Sep; 147(6):1612-1620. PubMed ID: 32141607
[TBL] [Abstract][Full Text] [Related]
6. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
[TBL] [Abstract][Full Text] [Related]
7. The clinical performance of primary HPV screening, primary HPV screening plus cytology cotesting, and cytology alone at a tertiary care hospital.
Choi JW; Kim Y; Lee JH; Kim YS
Cancer Cytopathol; 2016 Feb; 124(2):144-52. PubMed ID: 26457676
[TBL] [Abstract][Full Text] [Related]
8. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.
Fontham ETH; Wolf AMD; Church TR; Etzioni R; Flowers CR; Herzig A; Guerra CE; Oeffinger KC; Shih YT; Walter LC; Kim JJ; Andrews KS; DeSantis CE; Fedewa SA; Manassaram-Baptiste D; Saslow D; Wender RC; Smith RA
CA Cancer J Clin; 2020 Sep; 70(5):321-346. PubMed ID: 32729638
[TBL] [Abstract][Full Text] [Related]
9. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.
Wright TC; Stoler MH; Behrens CM; Sharma A; Zhang G; Wright TL
Gynecol Oncol; 2015 Feb; 136(2):189-97. PubMed ID: 25579108
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial.
Isidean SD; Mayrand MH; Ramanakumar AV; Gilbert L; Reid SL; Rodrigues I; Ferenczy A; Ratnam S; Coutlée F; Franco EL;
Int J Cancer; 2016 Dec; 139(11):2456-66. PubMed ID: 27538188
[TBL] [Abstract][Full Text] [Related]
11. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
[TBL] [Abstract][Full Text] [Related]
12. Cervical cancer rates after the transition from annual Pap to 3-year HPV and Pap.
Dinkelspiel H; Fetterman B; Poitras N; Kinney W; Cox JT; Lorey T; Castle PE
J Low Genit Tract Dis; 2014 Jan; 18(1):57-60. PubMed ID: 24022057
[TBL] [Abstract][Full Text] [Related]
13. Uptake of HPV testing and extended cervical cancer screening intervals following cytology alone and Pap/HPV cotesting in women aged 30-65 years.
Silver MI; Rositch AF; Phelan-Emrick DF; Gravitt PE
Cancer Causes Control; 2018 Jan; 29(1):43-50. PubMed ID: 29124542
[TBL] [Abstract][Full Text] [Related]
14. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
[TBL] [Abstract][Full Text] [Related]
15. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
16. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
Gage JC; Schiffman M; Katki HA; Castle PE; Fetterman B; Wentzensen N; Poitras NE; Lorey T; Cheung LC; Kinney WK
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25038467
[TBL] [Abstract][Full Text] [Related]
17. Why does cervical cancer occur in a state-of-the-art screening program?
Castle PE; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Schiffman M
Gynecol Oncol; 2017 Sep; 146(3):546-553. PubMed ID: 28606721
[TBL] [Abstract][Full Text] [Related]
18. The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics.
Gage JC; Raine-Bennett T; Schiffman M; Clarke MA; Cheung LC; Poitras NE; Varnado NE; Katki HA; Castle PE; Befano B; Chandra M; Rydzak G; Lorey T; Wentzensen N
Cancer Epidemiol Biomarkers Prev; 2022 Feb; 31(2):486-492. PubMed ID: 34789470
[TBL] [Abstract][Full Text] [Related]
19. Trends Over Time in Pap and Pap-HPV Cotesting for Cervical Cancer Screening.
MacLaughlin KL; Jacobson RM; Radecki Breitkopf C; Wilson PM; Jacobson DJ; Fan C; St Sauver JL; Rutten LJF
J Womens Health (Larchmt); 2019 Feb; 28(2):244-249. PubMed ID: 30614380
[TBL] [Abstract][Full Text] [Related]
20. Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort.
Kamineni A; Tiro JA; Beaber EF; Silverberg MJ; Wheeler CM; Chao CR; Chubak J; Skinner CS; Corley DA; Kim JJ; Balasubramanian BA; Paul Doria-Rose V;
Int J Cancer; 2019 Mar; 144(6):1460-1473. PubMed ID: 30353911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
